Skip to main content

Global reach and expertise in Rare Disease

MA = Marketing Authorisation

30

Available in 30+ countries

100

Number of employees

20

Established dedicated team in 20+ countries including the US and Europe
OUR PRODUCT

Over 1800+ patients treated around the world

Learn More
OUR MISSION

Transforming Rare Disease Treatment

We believe patients with a rare disease should have access to innovative treatment that improves their care and positively impacts their lives and those of their loved ones.

Our Work With the Medical Community

Our Research & Development

At Orphalan we strive to develop rare disease treatments to improve patients’ lives.

At Orphalan we identify, develop, and provide access to innovative treatments for patients with rare diseases to make a positive and meaningful difference. We work together by listening to patients and putting them first, which enables us to provide treatments and services that work for them.

Learn More

Read the latest news

All the latest company news, events and updates.

Orphalan becomes the first European company to enter in China’s Wilson Disease market

Orphalan becomes the first European company to enter in China’s Wilson Disease market

Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease

Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease

Tackling rare diseases: Wilson disease patient and millions more like her need help

Tackling rare diseases: Wilson disease patient and millions more like her need help

Why We Should Care About Rare Disease Research – Life Science Leader

Why We Should Care About Rare Disease Research – Life Science Leader

Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease

Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today